(Q55055249)

English

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thierry J Molina

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

René-Olivier Casasnovas

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Christian Récher

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bertrand Coiffier

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Corinne Haioun

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christophe Fermé

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Catherine Thiéblemont

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

André Bosly

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Guy Laurent

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Franck Morschhauser

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Hervé Ghesquières

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Fabrice Jardin

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Serge Bologna

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christophe Fruchart

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bernadette Corront

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jean Gabarre

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christophe Bonnet

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Maud Janvier

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Danielle Canioni

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jean-Philippe Jais

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Hervé Tilly

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Groupe d'Etude des Lymphomes de l'Adulte

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gilles Salles

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

0 references

publication date

1 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

378

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

9806

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1858-1867

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA damage-mediated induction of a chemoresistant niche

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Aggressive lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)61040-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55055249&oldid=1561065328"